Zanamivir

neuraminidase 1 ; Homo sapiens







162 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33588740 Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance. 2022 2
2 33556804 A Cost-Effectiveness Analysis of Neuraminidase Inhibitors for Influenza Virus Infections in an Adult-Outpatient Setting in Japan. 2021 May 1
3 33572654 Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis. 2021 Jan 31 1
4 33976181 Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models. 2021 May 11 1
5 34161726 Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections. 2021 Aug 18 4
6 34179969 Neuraminidase 1 is a driver of experimental cardiac hypertrophy. 2021 Sep 21 1
7 31368872 Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza. 2020 1
8 31664778 Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. 2020 Jan 1
9 31955521 Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons. 2020 May 1
10 32178606 Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018. 2020 Mar 16 1
11 32394467 A global treatments for coronaviruses including COVID-19. 2020 Dec 1
12 33154358 A universal dual mechanism immunotherapy for the treatment of influenza virus infections. 2020 Nov 5 1
13 30739429 Annual report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2016 2019 Feb 1 1
14 31203585 Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017 2019 Jun 17 1
15 32031540 Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient. 2019 1
16 32598620 [Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia]. 2019 Nov 15 2
17 29212895 Functional Metabolomics Characterizes a Key Role for N-Acetylneuraminic Acid in Coronary Artery Diseases. 2018 Mar 27 1
18 29397718 Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives. 2018 Mar 8 1
19 28315686 Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid. 2017 Apr 29 2
20 28502901 Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies. 2017 Oct 1
21 28655817 Antibody against Microbial Neuraminidases Recognizes Human Sialidase 3 (NEU3): the Neuraminidase/Sialidase Superfamily Revisited. 2017 Jun 27 1
22 28899310 Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015. 2017 Jun 30 1
23 29269445 Recurrent infection progressively disables host protection against intestinal inflammation. 2017 Dec 22 1
24 26905631 Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. 2016 Feb 24 1
25 27341624 Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses. 2016 Jul 14 8
26 27539435 Identification of single amino acid substitutions (SAAS) in neuraminidase from influenza a virus (H1N1) via mass spectrometry analysis coupled with de novo peptide sequencing. 2016 Aug 1
27 27845731 Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. 2016 Nov 11 2
28 25470818 Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. 2015 1
29 25673705 Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. 2015 Apr 1
30 25703253 Neuraminidase inhibitors: who, when, where? 2015 Mar 1
31 25980910 Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. 2015 Jun 15 1
32 26164940 [Susceptibility of Influenza B Viruses to Neuraminidase Inhibitors Isolated during 2013-2014 Influenza Season in Mainland China]. 2015 Mar 1
33 27004397 [Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season]. 2015 Dec 1
34 23983212 Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. 2014 Feb 15 1
35 24001233 Drugs against avian influenza a virus: design of novel sulfonate inhibitors of neuraminidase N1. 2014 2
36 24515341 Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. 2014 Feb 10 1
37 24560563 In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. 2014 Feb 1
38 24787736 Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor. 2014 Jul 1
39 24941871 From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? 2014 May 1
40 25163170 Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico. 2014 1
41 25314609 Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958. 2014 Dec 8 1
42 25352629 Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. 2014 Nov 15 1
43 23150231 Chemical probes for drug-resistance assessment by binding competition (RABC): oseltamivir susceptibility evaluation. 2013 Jan 2 2
44 23357777 Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets. 2013 Apr 1
45 23363310 European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. 2013 Jun 1
46 23369206 Recent progress and challenges in the discovery of new neuraminidase inhibitors. 2013 Apr 1
47 23422659 Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. 2013 1
48 23429702 Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. 2013 Apr 5 1
49 23553534 Effect of intravenous zanamivir on cardiac repolarization. 2013 Jul 1
50 23726392 Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. 2013 Jun 29 2